Extramural Funding Opportunities

This is an accordion element with a series of buttons that open and close related content panels.

NIDDK FUNDING ANNOUNCEMENTS

NOSI, K12, F99/K00, and RC2 AWARDS

Notice of Special Interest (NOSI): Addressing Health Disparities in NIDDK Diseases There are many diseases and disorders that disproportionately affect the health of underserved populations in the United States. African-Americans, Hispanic Americans, American Indians, Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, and rural populations experience much higher risks of and poorer health status than the majority population. Several of the diseases that disproportionately afflict underserved populations are high priority research areas for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The NIDDK seeks research to improve understanding of the causes of disparities in health and disability in the United States and reducing/eliminating health disparities directly related to the scientific areas within the mission of the NIDDK. The overall objective of this NOSI is to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is recognized that both biologic and non-biologic factors may be operating in these underserved populations. Research approaches may include metabolic, genetic, genomic, proteomic, proteogenomics, behavioral, clinical and/or epidemiologic studies in representative populations. Advantage might be taken of extant cohort studies that have been established for investigation of diabetes or other diseases. Collaboration among investigators of these established cohorts would be desirable, so that these studies might jointly develop protocols and evaluate findings. Alternatively, investigators may propose to start a new cohort, appropriately powered, to capture the current risks and outcomes in the era of new medications for some of the diseases. Such studies of current risks might appropriately be based in large HMOs or clinical practices with structure and data management practices conducive to efficient and cost-effective analyses. Posted 12/16/2019. Expires 1/8/2023.

Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. Research Project data are expected to support one or more follow-on independent grant applications (e.g., R01s) submitted by Research Project Team investigators. The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Project Team to help ensure the research aims are met and to aid them in their successful integration into the broader urologic research field. The Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program. Posted 11/28/2022. Expires 10/20/2023.

The Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Transition Award (F99/K00) is designed to help recruit truly exceptional graduate students, who are currently NOT involved in K, U, or H research and provide them a stable transition into a postdoctoral research experience focused on KUH research. This is an exceptional opportunity to recruit graduate students with diverse perspectives from fields including, but not limited to, engineering, statistics, data science, imaging, biochemistry, neuroscience and genetics. Prospective mentors and applicants are strongly encouraged to contact the NIDDK Program Official, Christine Maric-Bilkan (christine.maric-bilkan@nih.gov) to discuss eligibility and program goals. Posted 3/17/2022. Expires 4/2/2025.

High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK.  The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK. Posted 11/30/2021.  LOI due six weeks prior to application due date (next 6/1/22). Expires 10/31/24.

R21 AWARDS

Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) Scientific discovery is often catalyzed by technological innovations. The kidney, urinary tract, blood, and blood-forming organs present unique technological challenges. To address these challenges, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to develop novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of kidney, urologic, or hematologic diseases. This Funding Opportunity Announcement (FOA) is intended to support tool or technology development projects, opening new areas of science or translational research. The projects supported by this FOA could involve proof-of-concept studies, prototyping, optimization of a technology for the unique anatomy or physiology of these organ systems, and refinement of technical specifications for subsequent deployment of the technology in laboratory or clinical settings. Applications submitted to this FOA should be highly innovative. These studies should break new ground or extend previous discoveries toward new directions or applications. Applications to this FOA should include projects distinct from those that can be supported through the traditional R01 grant mechanism. For example, long-term projects, or projects designed to increase knowledge in a well-established area, are not appropriate for this FOA. Posted 5/16/2020. Standard due dates. Expires 5/8/2023.

Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Posted 8/20/2021. Standard due dates. Expires 9/8/2024.

RO1 AWARDS

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators’ specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs), including the NIDDK. The R01 is the original, and historically the oldest, grant mechanism used by the NIH to support health-related research and development. Research grant applications are assigned to participating ICs based on receipt and referral guidelines and applications may be assigned to multiple participating ICs with related research interests. Applicants are encouraged to identify a participating IC that supports their area of research via the R01 IC-Specific Scientific Interests and Contact website and contact Scientific/Research staff from relevant ICs to inquire about their interest in supporting the proposed research project. Posted 5/5/2020. Standard due dates. Expires 5/8/2023.

Research Project Grant (Parent R01 Clinical Trial Required) The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators’ specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs), including the NIDDK. The R01 is the original, and historically the oldest, grant mechanism used by the NIH to support health-related research and development. All applications submitted to this Parent Funding Opportunity Announcement must propose clinical trial(s). Research grant applications are assigned to participating ICs based on receipt and referral guidelines and many applications are assigned to multiple participating ICs with related research interests. Applicants are encouraged to identify a participating IC that supports their area of research via the R01 Clinical Trial Required IC-Specific Scientific Interests and Contact website and contact Scientific/Research staff from relevant ICs to inquire about their interest in supporting the proposed research project. Posted 5/5/2020. Standard due dates. Expires 5/8/2023.

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs), including the NIDDK, based on their scientific missions. Posted 5/5/2020. Standard due dates. Expires 5/8/2023.

Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required. Posted 3/31/2020. Standard due dates. Expires 5/8/2023.

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs), including the NIDDK, based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials. Posted 11/9/2020. Upcoming special application due dates: January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023. Expires 12/29/2023.

T32 AWARDS

T32: Medical Student Research Training Supplement The Medical Student Research Training (MSRT) program provides mentored support for medical students interested in taking a year off from their medical school studies to work in an academic research lab. This support is via a supplement to a training grant (T32) in the appropriate area of research. A list of currently funded T32 program locations with the Principal Investigator contact information is available. Providing the opportunity for students to interrupt their medical school studies for up to 12 months to pursue a research project should help them solidify their decisions to pursue a research career, focus their research interests, and provide a background for future training and career development programs once they have completed their medical training. Posted 10/18/2021. Application Due Date(s) – January 18, 2022; April 18, 2022; January 18, 2023; April 18, 2023; January 18,2024; and April 18, 2024

COOPERATIVE AGREEMENT AWARDS

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (observational studies) – This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. Posted 12/23/2020. Standard due dates. Expires 1/08/2024.

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement(clinical trials) – This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. Posted 12/23/2020. Standard due dates. 1/08/2024.

NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements  NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The activities required in the U34 will depend on the type of study (e.g., epidemiologic study, drug/device/biologics trial, behavior intervention). Because the purpose of the U34 is primarily for the conduct of administrative tasks needed to prepare for participant recruitment, activities involving human subjects will generally not be conducted during the U34 phase; however, brief activities involving interactions with individuals similar to those expected to participate in the full study during the U01 award may be allowed in order to aid in development of study procedures or operations (e.g., assessing usability of a form, device calibration, workflow optimization). As noted above, the U34 period may also include stakeholder engagement activities. The U34 is designed to: 1) permit early peer review of the rationale for the proposed clinical study; 2) permit assessment of the design and protocol of the proposed study; 3) provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Posted 12/23/2020. Upcoming special application due dates: February 17, 2022; October 13, 2022; June 8, 2023; February 15, 2024. Upcoming LOI due dates: January 17, 2022; September 13, 2022; May 8, 2023; January 15, 2024. Expires 2/16/2024.

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later stage therapeutics development and preclinical efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. Applicants are strongly encouraged to discuss research priorities with the Scientific Contacts for each division. The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called “therapeutic leads”) such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, identifying new therapeutic uses for existing compounds, or identifying mechanism of action for therapeutic leads. Posted 2/4/2022. Expires 1/8/2025.

Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional) The SUITOR program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described in the RFA. Posted 12/2/2021. Expires 5/8/2025.

OTHER AWARDS

HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery The purpose of this Notice of Special Interest (NOSI) is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to improve the translational application of animal models and/or outcome measures for the development of non-addictive analgesics. Ideally, models or measures proposed for this NOSI would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This NOSI is not specific for any one or group of pain conditions. Projects focused on acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, obstetric pain, gynecologic pain, post stroke pain, myofascial pain, painful disorders of the orofacial region, pain co-occuring with substance use disorders, and other conditions will be considered. In addition to replication and validation of more commonly used translational animal models of pain, the development of animal models of pain for understudied pain conditions, age groups or less developed models is also encouraged. Posted 7/14/2022. Expires 6/25/2025.

NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed) The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository’s website. Applicants must include a volume and impact assessment report from the NIDDK Central Repository with the X01 Application to document sample availability. Posted 6/29/2022. Expires 6/27/2025.

OTHER NIH FUNDING ANNOUNCEMENTS

NIH Loan Repayment Plan (LRPs):

The NIH Loan Repayment Programs (LRPs) are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The escalating costs of advanced education and training in medicine and clinical specialties are forcing some scientists to abandon their research careers for higher-paying private industry or private practice careers. The LRPs counteract that financial pressure by repaying up to $50,000 annually of a researcher’s qualified educational debt in return for a commitment to engage in NIH mission-relevant research. Since tomorrow’s medical breakthroughs will be made by investigators starting in their research careers today, the LRPs represent an important investment by NIH in the future of health discovery and the wellbeing of the Nation.

From the National Institute on Aging:

Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)  The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) curriculum or methods development; (2) courses for skills development; and/or (3) research experiences. Posted 1/16/2020. Standard due dates. Expires 1/26/2023.

Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging; research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. Posted 8/23/2021. Standard due dates. Expires 9/8/2023.

Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. Posted 7/7/2022. Expires 9/26/2025.

From other NIH institutes:

  • Research Supplements to Promote Diversity in Health-Related Research – PA-21-071. NIH-wide announcement. Funds are available to program directors and principal investigators holding specific types of NIH research grants for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. Administrative supplements must support work within the scope of the original project. The application deadline varies by Institute or Center. This is an administrative supplement; clinical trial not allowed. Posted 11/16/2020. Standard due dates. Expires 5/8/2023.
  • Notice of Special Interest (NOSI): Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional) The mission of the NIH is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NIH is committed to supporting research that will increase scientific understanding of the health and well-being of various population and subpopulation groups and that will help to establish the effectiveness of evidence-based health interventions and services for individuals within these groups. NIH places high priority on research with populations that have distinct health risk profiles and who have also received insufficient attention from the scientific research enterprise. To this end, this Notice of Special Interest (NOSI) announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate sexual and gender minority (SGM) populations or SGM-relevant research questions. SGM populations include, but are not limited to, those populations described in NOT-OD-19-139. Basic, social, behavioral, clinical, translational, and health services research relevant to the missions of the sponsoring NIH Institutes or Centers (ICs) may be proposed in response to this solicitation. Potential applicants are encouraged to review the most recent annual Portfolio Analysis of NIH-funded SGM research to identify potential research gaps that may be relevant to this NOSI. More information about the SGM administrative supplements program and previously awarded research projects can be found on the SGMRO website. Posted 12/2/2021. Expires 2/1/2024.
  • Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 – Clinical Trial Optional) Agency for HealthCare Research and Quality. The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Posted 2/9/2021. Standard due dates. Expires: 7/18/2024.
  • Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00). The purpose of this program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH’s Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. Two awards are available: (1) K99/R00 Independent Clinical Trial Not Allowed; and (2) K99/R00 – Independent Clinical Trial Required. Posted 8/17/2021. Standard due dates. Expires 9/8/2024.
  • Large Research Projects for Prevention of Healthcare-Associated Infections (R01) This Funding Opportunity Announcement (FOA) invites grant applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). Posted 7/7/2021. Standard due dates. Expires 5/27/2025.

INSTITUTION-SPECIFIC CTSA STAKEHOLDER ENGAGEMENT FUNDING

*Follow the links to specific funding opportunities for more detailed information regarding deadlines and requirements. The deadlines for some of the following opportunities may have passed for FY2021 but have been identified as reoccurring opportunities.


Albert Einstein College of Medicine – Institute for Clinical & Translational Research (ICTR) Funding

  • Catalytic Seed Grants
    • We invite applications from faculty members seeking seed funding to provide data for the development of extramural grant applications. Awards of up to $5,000 will be provided to investigators who will acquire new data to generate proposals for additional funding. Funds must be used for projects that will use ICTR Cores and Resources. Applications must be planned in consultation with the director(s) of the core or resource, who will help develop and approve the requested budget. Funds may not be used to purchase equipment or for salary support. Projects supported under this program must be clinical or translational in design or implementation. Priority for funding will be given to the current ICTR focus areas: (1) Pediatric determinants of adult health, (2) Experimental therapeutics, (3) Patient-centered outcomes research utilizing Montefiore Health System data.

Columbia University – Irving Institute for Clinical & Translational Research (IICTR) Funding

  • Collaborative and Multidisciplinary Pilot Research (CaMPR) General and Integrating Special Populations (ISP) Pilot Award
    • The CaMPR and CaMPR-ISP program focuses on the innovative assembly of new teams to gather preliminary data to address unresolved clinical, translational and public health problems with novel approaches informed by interdisciplinary and multidisciplinary collaboration. Projects that use a community-engaged approach to research are encouraged (CECR).
  • Community-Based Participatory Research Scholars and Awards Program
    • The Community Based Participatory Research Scholars and Awards Program is an innovative training and pilot funding opportunity for Columbia University faculty and administrators of not-for-profit organizations serving Upper Manhattan and The Bronx. The CBPR Program is designed to foster community-engaged research by giving participants structured training and practical experience in CBPR methodology. Up to five academic-community dyads are selected for the course. Academic-community co-instructors teach the CBPR course to model the partnership process. Upon completion of the training course, dyads are eligible to apply for a one-year CBPR pilot award of $30,000.

Duke University –Clinical & Translational Science Institute (CTSI) Funding

  • Duke/NCCU Collaborative Translational Research Awards
    • This pilot program is designed to facilitate novel clinical, population, and translational research that applies or accelerates discovery into testing in clinical or population settings. Projects must demonstrate stakeholder engagement and a high translational potential with a clear path for continued development to move into clinical practice, generate new clinical guidelines, or other applications via subsequent grant support, new company formation, licensing, not-for-profit partnering, an evidence base that changes practice or other channels.
  • Duke/NC State Translational Research Agreement
    • This pilot program is designed to facilitate novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings. Projects must demonstrate stakeholder engagement and high translational potential with a clear path for continued development to move into clinical practice, generate new clinical guidelines, or other applications via subsequent grant support, new company formation, licensing, not-for-profit partnering, an evidence base that changes practices, or other channels.
  • Duke CTSI Special Populations Pilot
    • The purpose of the Special Populations Pilot program is to facilitate novel clinical and translational research that promotes health equity for groups who have traditionally been under-represented in health research or excluded altogether. Projects must have strong potential to inform subsequent grant applications for external funding. Pilot awards will be $25,000 (direct costs only); applications that include a strong community stakeholder-academic partnered approach will be eligible for an additional $10,000 for a total of $35,000 in pilot funding for a team that includes a strong community stakeholder-academic partnered approach. (see Community-Engaged Approaches below). Proposals from early stage and new investigators and proposals with collaborations across Duke Departments or Schools are highly encouraged.
  • CTSI Translational Accelerator Research Funding Agreement
    • The Duke CTSI Translational Accelerator Research Funding Agreement provides up to $125,000 (direct costs only) to support novel translational research that applies or accelerates discovery into testing in clinical or population settings. Projects must demonstrate stakeholder engagement and high translational potential for continued development to move into clinical practice, generate new clinical guidelines, or other applications via subsequent grant support, new company formation, licensing, not-for-profit partnering, an evidence base that changes practice, or other channels.
  • CTSI Population Health Improvement Awards Program
    • This Awards program aims to engage community and academic partners in collaborative research that promotes novel ideas to improve community and population health. Duke CTSI, home of the National Institutes of Health’s Clinical and Translational Science Award at Duke, will provide approximately $100,000 annually to support pilot awards that can be used to either a) develop new community-research partnerships or b) foment already existing community and research partnerships that aim to develop and test effective solutions to improve community and population health. These partnerships and innovations can originate from community stakeholders or from Duke research partners but they must involve both community and research collaborators.
  • Carolinas Collaborative
    • This multi-site CTSA Translational Research Pilot Program is offering the opportunity for investigators to use electronic health records from multiple health systems in clinical research. Projects must demonstrate high translational potential with a clear path to subsequent grant support for a cohort study or clinical trial. Population health improvement projects should demonstrate significant stakeholder involvement to move it into broader practice patterns, clinical guidelines, and other applications.

Medical College of Wisconsin – Clinical & Translational Science Institute (CTSI) Funding

  • 2021 CTSI Pilot/Integrated Clinical and Research Ensemble (ICRE) Award
    • The vision is to organize and leverage clinical/translational research to improve patient health and health care. The mission of an ICRE is to integrate clinical and research faculty, community stakeholders and health system representatives in highly innovative and efficient units/Ensembles to get more treatments and interventions more quickly to more patients and our community.

University of Alabama at Birmingham – Center for Clinical & Translational Science (CCTS) Funding

  • CCTS Interdisciplinary Network Pilot Program
    • Through the CCTS Pilot Program, we seek to (a) ameliorate disparities in diseases that disproportionately affect minority and special populations across the CCTS Partner Network and (b) develop the future translational research workforce by fostering collaboration, team science and innovative discovery. Special consideration will be given to projects that include community-engaged research.
  • Voucher Programs
    • The mission of the Center for Clinical and Translational Science (CCTS) is to address disparities and diseases disproportionately represented within the Deep South as we accelerate discovery to improve human health. Vouchers help overcome barriers to conducting mission-aligned investigation by connecting investigators with clinical, translational or community-based research goals to the facilities, resources and expertise they need. Vouchers are intended for active research efforts that are ready to use these resources immediately.

University of California San Francisco – Clinical & Translational Science Institute (CTSI) Funding

  • Pilot for Research on Racism Impacting Black People
    • The UCSF Office of Research has committed to the goal of anti-racism and racial equity in research. As one action for this initiative, the Office of Research has convened campus partners to create an anti-racism research pilot grant program. Funding for this initiative is provided by the Clinical and Translational Science Institute (CTSI), Academic Senate, School of Medicine’s Research Evaluation and Allocation Committee (REAC), and the Research Development Office. Community-academic partnerships are encouraged and may include local, county, or state governments, police departments, court systems, and/or high-impact nonprofits or community-based organizations.

University of Michigan – Michigan Institute for Clinical & Health Research (MICHR) Funding

  • Catalyst Award
    • The Catalyst Award aims to support early career faculty (at the Assistant Professor or earlier ranks) in advancing their translational research careers. Applicants should propose a research plan that will help them to generate the data needed to strengthen hypotheses for subsequent extramural applications. We encourage applications for innovative projects at all stages of translation (T1-T4) that use one of the following approaches to research: investigator-initiated research or community-based participatory research (CBPR).
  • Building Capacity for Research and Action Award
    • MICHR has partnered with Community-Based Organization Partners (CBOP) to establish a funding opportunity to address health consequences stemming from the Flint Water Crisis. The Building Capacity for Research and Action (BCRA) Award will support community-engaged research partnerships and projects addressing community health priorities in Flint, Mich.
  • Pathway Awards
    • To support faculty along their career trajectories, MICHR has developed two pathway awards – Pathway to First Grant and Pathway to Independence. These awards are intended to help researchers obtain preliminary data that will strengthen extramural grant applications and support the development of long-term research goals. For the pathway awards, we encourage applications for innovative projects at all stages of translation (T1-T4) that use one of the following approaches to research: investigator-initiated research, collaborative research, or community-based participatory research (CBPR).
  • Community-University Partnership Seed (CUPS)
    • The Community-University Partnership Seed grant (CUPS) promotes the formation and maintenance of community-university partnership activities in support of research projects that address community-defined health priorities. CUPS grant funding supports these partnerships at any phase of the research process. Applicants who are in the early stages of forming their partnership may have a greater focus on relationship building, exploration of shared areas of interest, and creation of the partnership structure. Applicants who are already engaged in an established partnership may be focused on different activities, such as the dissemination of research findings or evaluation of the partnership process. These activities would support the ongoing maintenance, sustainability, and/or evaluation of the research partnership.

University of Pennsylvania – Institute for Translational Medicine and Therapeutics (ITMAT) Funding

  • CEAR CTSA Pilot Grant Program
    • The Community Engagement and Research (CEAR) core of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania is sponsoring a pilot grant program to fund research with public and community health relevance. The CEAR Core is seeking proposals that foster community-based research, especially studies that use a participatory framework. This includes research conducted in community settings or using a participatory research framework that actively involves community stakeholders in the conceptualization, design, implementation, and/or evaluation. “Community” is defined broadly to include populations in neighborhoods and organizations, including health care settings.

University of Pittsburgh – Clinical and Translational Science Institute (CTSI) Funding

  • CRISP: CTSI’s Research Initiative for Special Populations
    • CRISP offers campus investigators up to $25,000 in funding to support research initiatives that work with groups that are frequently underrepresented in research. Applications that demonstrate a meaningful partnership with a community organization may be eligible for an additional $5,000 in bonus funding (see the bonus round section below for additional information).
  • The Pitt Innovation Challenge 2021
    • The Pitt Innovation Challenge (PInCh®) 2021 is seeking your bold solution to a challenging health problem. We encourage proposals from any discipline and on any topic that impacts health. Ideas can span the spectrum of health and healthcare, including disease prevention, diagnostics, treatments, interventions, predictive solutions, patient care, provider and patient tools, and community programs. We encourage projects that create new connections within the academic community, and among universities and community organizations.
  • Wordout Community Research Dissemination Challenge
    • The Community PARTners Core at the Clinical and Translational Science Institute (CTSI) is now accepting applications for the WORDOUT Community Research Dissemination Challenge. WORDOUT is an exciting program that matches researchers from the University of Pittsburgh with local community organizations to help get the “word out” about the latest in research dissemination. We are once again matching community organizations with researchers to work together to both share lived experiences of folks in the community, and think about creative ways to disseminate research.

University of Wisconsin-Madison – Institute for Clinical & Translational Research (ICTR) Funding

  • Stakeholder & Patient Engaged Research (SPER) Pilot Award
    • The goal of this Stakeholder and Patient Engaged Research (SPER) RFA is to provide support for activities that will strengthen a competitive application for external funding for research requiring strong stakeholder engagement as a foundation for a successful application. This includes but is not limited to PCOR. New or previously unsuccessful applicants to PCOR funders are encouraged to apply. (Deadline passed)
  • Clinical & Community Outcomes Research (CCOR) Pilot Award
    • The goal of the Clinical & Community Outcomes Research (CCOR) Pilot Award is to support excellent, community-partnered health research that solves problems translating knowledge into improvements in clinical practice, community programs and health policy. This pilot award may also support the development of interventions that require individual, organizational, or system behavior change. (Deadline passed)
  • Collaborative Health Equity Research (CHER) Pilot Award
    • To support new community-engaged research projects focused on health disparities/inequities wherein the PI is an early stage investigator, e.g., assistant professor, and a senior co-investigator is engaged to ensure a mentored experience and to connect the research team with relevant stakeholders. (Deadline passed)
  • Dissemination & Implementation Research (D&I) Pilot Award
    • To support research that addresses how to best ensure that evidence-based strategies/interventions/programs are effectively delivered in clinical and community health practice settings and impact policy. The successful grantee will use the results of this award to seek further extramural peer reviewed funding for the research. (Deadline passed)

Washington University in St. Louis – Institute of Clinical & Translational Sciences (ICTS) Funding

  • Clinical and Translational Research Funding Program (CTRFP)
    • As an internal grant funding program of the ICTS, the Clinical and Translational Research Funding Program (CTRFP) awards projects that promote the translation of scientific discoveries into improvement in human health. Awards will be considered for Community-Engaged Research Projects that involve established partnerships with communities and/or stakeholders whose health and well-being and/or service provision could be most impacted by the research.
  • Partnership Development & Sustainability Support (PDSS)
    • Through our Center for Community Health Partnership & Research, the ICTS launched the PDSS to provide ICTS investigators and their community partner(s) with up to $10,000 over a 9-month period to develop the trust, infrastructure, capacity, and skills needed to support future collaborative grant opportunities. The PDSS is open to new partnerships in development, as well as existing partnerships.

OTHER FUNDING OPPORTUNITIES

AUA Funding Announcements

2023 Residency Research Award Competition Residency Research Awards provide motivated and exceptional urology residents with mentored training to enable them to build momentum toward a career that includes urologic research. Awardees receive $10,000 for research supplies and other resources needed to conduct a 3-12 month research project during the resident’s research training period. The 2023 competition is now open! Letters of Intent are due by 5 pm ET Thursday, December 1, 2022. Proposals are due 5 pm ET Thursday, January 12, 2023. Please contact grantsmanager@AUAnet.org with any questions.

Boston Scientific Medical Student Innovation Fellowship

The new Boston Scientific Medical Student Innovation Fellowship supports current or matriculating medical students interested in translating urology research into innovation by engaging them in a fellowship mentored by world-class urologic scientists. Applications open Fall 2022 for one award that will begin July 2023. With host institutions matching Urology Care foundation funds, the awardee will receive a $20,000 stipend for a 12-month research project. Strong preference to award applicants from groups underrepresented in urology and/or projects focused on addressing health disparities in urology. The 2023 competition is now open! Applications are due Thursday, December 1, 2022. Please contact grantsmanager@AUAnet.org with any questions.

Other Funding Announcements

Innovative Science Accelerator Program (ISAC) The ISAC Award provides seed funding for exceptionally innovative, disruptive (high-risk/high-reward) research relevant to Kidney-Urologic-Hematologic communities that has the potential to lead to groundbreaking or paradigm-shifting results that will change the field. ISAC awards are NOT Pilot & Feasibility projects for the generation of more preliminary data for traditional NIH applications (e.g., R01). Three-page applications are accepted on a rolling basis and reviewed three times a year. Investigators may request up to $100,000 (direct + indirect costs) total costs for one year. Standard application due dates: April 15, Aug 15, Dec 15.

Ruth L. Kirschstein National Research Service Award Institutional Research Training Awards NRSA awards support the training of biomedical, behavioral, and clinical researchers through individual pre- and postdoctoral fellowships, and institutional research training grants. Search for funding opportunities by career stage HERE. NIH now provides childcare cost support to full-time predoctoral and postdoctoral trainees appointed on NRSA institutional research training awards. The NRSA childcare costs apply to each full-time predoctoral or postdoctoral NIH-NRSA-supported institutional research training award appointment. Each trainee is eligible to receive $2,500 per budget period for childcare costs provided by a licensed childcare provider.